Potential conflict of interest: Nothing to report.
Comment on “angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice”†
Article first published online: 29 SEP 2009
Copyright © 2009 American Association for the Study of Liver Diseases
Volume 51, Issue 2, page 718, February 2010
How to Cite
Lenos, M. G. and Tsaniklidou, S.-M. (2010), Comment on “angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice”. Hepatology, 51: 718. doi: 10.1002/hep.23350
- Issue published online: 25 JAN 2010
- Article first published online: 29 SEP 2009
- Accepted manuscript online: 29 SEP 2009 12:00AM EST
To the Editor:
In their article in the September 2009 issue of HEPATOLOGY, Österreicher et al. conclude with a protective role for angiotensin-converting enzyme 2 (ACE2) on liver injury.1 ACE2 acts to counterbalance up-regulation of the renin-angiotensin system (RAS) through degradation of angiotensin II to angiotensin 1-7. Based on previous reports on other disease models of RAS overactivity, we would like to highlight another potential anti-RAS mechanism. In these models, immunoassay studies have identified the presence of circulating antibodies against ACE and angiotensin II considered to exert a neutralizing effect.2, 3 Currently, no studies evaluating the levels of serum/tissue anti-RAS antibodies in chronic liver disease models are reported in the literature. It is possible that standardization of their titers could prove to be of prognostic significance.
- 1Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. HEPATOLOGY 2009; 50: 929–938., , , , , , et al.
- 2Diagnostic implications of detecting antibodies to angiotensin-converting enzyme and its substrates [in Russian]. Klin Med (Mosk) 2003; 81: 31–34., , , , , , et al.
- 3Autoantibodies to vasoactive peptides and angiotensin converting enzyme in patients with systemic diseases of the connective tissue. Ter Arkh 2001; 73: 20–25., , , , , , et al.
Michael G. Lenos M.D.*, Sofia-Maria Tsaniklidou M.D., * Department of Pathology, General Hospital of Athens ‘HIPPOCRATION’, Athens, Greece, Department of Microbiology, General Hospital of Athens ‘GENNIMATAS’, Athens, Greece.